Multiple Myeloma

Chimeric antigen receptor (CAR) T-cell therapy can engineer T cells to target malignant cells in multiple myeloma.

The monotherapy is compared with the combination regimen of elotuzumab plus pomalidomide and dexamethasone in adult patients with relapsed or refractory multiple myeloma.

An interdisciplinary discussion addresses the disparity in availability and use of these therapies across the continuum of care.

The quadruplet regimen added bortezomib to the current standard of care, which is a triplet regimen of isatuximab, lenalidomide, and dexamethasone for patients with transplant-ineligible, newly diagnosed multiple myeloma (NDMM TI).

Observation time on subsequent injections of subcutaneous daratumumab may be safely removed from institutional policies to reduce chair time.

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

The study showed that belantamab mafodotin plus pomalidomide and dexamethasone (BPd) significantly improved progression-free survival compared to pomalidomide plus bortezomib and dexamethasone (PVd).

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

Investigators assessed the efficacy of BsAb5003 in treating multiple myeloma, with the results showing that the therapy may be an effective treatment approach.

Researchers from the University of Leipzig Medical Center identify multiple biomarkers associated with the success of CAR T cell therapy in relapsed multiple myeloma.

Medical professionals share insights on treatment considerations and patient selection for bispecific antibody therapy and the process for referring patients to other institutions for care.

Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.

Ke Ning, MD, discusses the impact of the introduction of bispecific antibodies for treating patients with relapsed or refractory multiple myeloma.

CAR T-cells specifically targeting FCRL5, when integrated with IL-15, may improve cytotoxicity, thereby enhancing the therapeutic potency of these cells.

The vice president of pharmacy operations at American Oncology Network says that pharmacists can contribute by educating patients and offering resources for support and treatment adherence.

Integration of these agents requires supportive care considerations for cytokine release syndrome, neurotoxicity, infection, and antigen-specific toxicities to ensure optimal care of patients with multiple myeloma receiving T-cell–engaging therapies.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some common challenges pharmacists may be facing when looking to operationalize bispecifics at their facilities.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, discusses the role of the pharmacist in relation to bispecific care team readiness and patient readiness.

In addition to emerging treatment options, the speakers addressed the importance of individualized decision-making when treating patients with multiple myeloma.

Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, addresses some of the considerations for bispecifics in relation to facility readiness at different sites and among different stakeholders.

The indication is for adult patients with multiple myeloma who are refractory to lenalidomide and have previously received at least 1 line of therapy.

Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.

There are unique complexities when implementing bispecific antibodies, including site of care considerations, monitoring, and management of adverse events.

FDA-approved BiTE therapies for relapsed/refractory multiple myeloma show promising response rates, offering off-the-shelf alternatives to CAR T therapy.

The approval expands the prior indication of idecabtagene vicleucel (Abecma; Bristol Myers Squibb), which will make the drug available to patients in earlier lines.

Unlike conventional monoclonal antibodies, BsAbs possess dual binding domains that target 2 distinct antigens simultaneously.

Panelists summarize key takeaways on using bispecific antibodies for multiple myeloma treatment.